{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:37:41Z","timestamp":1787445461496,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0008\/0010"],"award-info":[{"award-number":["RD16\/0008\/0010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0008\/0010"],"award-info":[{"award-number":["RD16\/0008\/0010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0008\/0010"],"award-info":[{"award-number":["RD16\/0008\/0010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009042","name":"Universidad de Sevilla","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009042","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antibody\u2013drug conjugates consist of a monoclonal antibody attached to a cytotoxic therapeutic molecule by a connector. This association allows a highly specific therapy, which increases their effectiveness and decreases their potential toxicity. This new therapy emerged approximately 20\u00a0years ago; since then, numerous combinations have appeared in the field of treatment-related neoplasms as an alternative for patients who do not achieve good results with conventional treatment options. Adverse effects of these drugs on the ocular surface are frequent and varied. Their prevalence ranges from 20 to 90% depending on the drug and administration condition, probably due to multiple receptor-mediated factors or mechanisms not mediated by specific receptors, such as macropinocytosis. These adverse events can greatly limit patients\u2019 comfort; thus, the objectives of this article were, in the first place, to compile the information currently available on different types of adverse effects of antibody\u2013drug conjugates on the ocular surface, including pathophysiology, prevalence, and treatment, and in second place, to contribute to the correct identification and management of these events, which will result in a lower rate of cessation of treatment, which is necessary for the survival of candidate patients.<\/jats:p>","DOI":"10.1007\/s12094-023-03261-y","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T21:01:49Z","timestamp":1689454909000},"page":"3086-3100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Adverse events of antibody\u2013drug conjugates on the ocular surface in cancer therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Sandra","family":"Dom\u00ednguez-Llamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4922-027X","authenticated-orcid":false,"given":"Manuel","family":"Caro-Magdaleno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mataix-Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Avil\u00e9s-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Romero-Barranca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Rodr\u00edguez-de-la-R\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"3261_CR1","doi-asserted-by":"publisher","first-page":"110009","DOI":"10.1016\/j.biopha.2020.110009","volume":"125","author":"SS Bashraheel","year":"2020","unstructured":"Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother. 2020;125:110009. https:\/\/doi.org\/10.1016\/j.biopha.2020.110009.","journal-title":"Biomed Pharmacother"},{"key":"3261_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3261_CR3","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","volume":"25","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25:4764. https:\/\/doi.org\/10.3390\/molecules25204764.","journal-title":"Molecules"},{"key":"3261_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34:1015\u201335. https:\/\/doi.org\/10.1007\/s12325-017-0519-6.","journal-title":"Adv Ther"},{"key":"3261_CR5","doi-asserted-by":"publisher","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","volume":"11","author":"A Wahab","year":"2021","unstructured":"Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol. 2021;11:678634. https:\/\/doi.org\/10.3389\/fonc.2021.678634.","journal-title":"Front Oncol"},{"key":"3261_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.008.","journal-title":"Pharmacol Ther"},{"key":"3261_CR7","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","volume":"24","author":"JA Thompson","year":"2018","unstructured":"Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, et al. Phase I trials of anti-ENPP3 antibody\u2013drug conjugates in advanced refractory renal cell carcinomas. Clin Cancer Res. 2018;24:4399\u2013406. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0481.","journal-title":"Clin Cancer Res"},{"key":"3261_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9:889\u2013911. https:\/\/doi.org\/10.1007\/s40123-020-00280-8.","journal-title":"Ophthalmol Ther"},{"key":"3261_CR9","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","volume":"78","author":"H Zhao","year":"2018","unstructured":"Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, et al. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody\u2013drug conjugates. Cancer Res. 2018;78:2115\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3202.","journal-title":"Cancer Res"},{"key":"3261_CR10","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ophtha.2020.07.047","volume":"127","author":"A Rousseau","year":"2020","unstructured":"Rousseau A, Michot JM, Labetoulle M. Belantamab Mafotodin-induced epithelial keratopathy masquerading myopic surgery. Ophthalmology. 2020;127:1626. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.047.","journal-title":"Ophthalmology"},{"key":"3261_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2217\/fon-2020-1269","volume":"17","author":"AK Nooka","year":"2021","unstructured":"Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, et al. Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021;17:1987\u20132003. https:\/\/doi.org\/10.2217\/fon-2020-1269.","journal-title":"Future Oncol"},{"key":"3261_CR12","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/1538-7445.AM10-2436","volume":"70","author":"JM Gudas","year":"2010","unstructured":"Gudas JM, Torgov M, An Z, Jia XC, Morrison KJ, Morrison RK, et al. Abstract 2436: AGS-16M8F is a novel antibody drug conjugate (ADC) for treating renal and liver cancers. Cancer Res. 2010;70:2436. https:\/\/doi.org\/10.1158\/1538-7445.AM10-2436.","journal-title":"Cancer Res"},{"key":"3261_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/onco.13628","volume":"26","author":"C Kollmannsberger","year":"2021","unstructured":"Kollmannsberger C, Choueiri TK, Heng DYC, George S, Jie F, Croitoru R, et al. A randomized phase II study of AGS-16C3F versus axitinib in previously treated patients with metastatic renal cell carcinoma. Oncologist. 2021;26:182\u2013361. https:\/\/doi.org\/10.1002\/onco.13628.","journal-title":"Oncologist"},{"key":"3261_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","volume":"13","author":"S Golfier","year":"2014","unstructured":"Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014;13:1537\u201348. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0926.","journal-title":"Mol Cancer Ther"},{"key":"3261_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.19.02085","volume":"38","author":"R Hassan","year":"2020","unstructured":"Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020;38:1824\u201335. https:\/\/doi.org\/10.1200\/JCO.19.02085.","journal-title":"J Clin Oncol"},{"key":"3261_CR16","unstructured":"Cancer Institute (2017) N. Common terminology criteria for adverse events (CTCAE). v.5.0 [Internet]. https:\/\/www.meddra.org\/: 18\u201323"},{"key":"3261_CR17","unstructured":"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 71471223, Aprutumab ixadotin; [cited 2023 Jan. 3]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Aprutumab-ixadotin"},{"key":"3261_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","volume":"14","author":"SB Kim","year":"2019","unstructured":"Kim SB, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody\u2013drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol. 2019;14:591\u2013601. https:\/\/doi.org\/10.1007\/s11523-019-00670-4.","journal-title":"Target Oncol"},{"key":"3261_CR19","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. https:\/\/doi.org\/10.3389\/fimmu.2018.01821.","journal-title":"Front Immunol"},{"key":"3261_CR20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(18)30576-X.","journal-title":"Lancet Oncol"},{"key":"3261_CR21","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","volume":"105","author":"R Popat","year":"2020","unstructured":"Popat R, Warcel D, O\u2019Nions J, Cowley A, Smith S, Tucker WR, et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: A case series from the first-time-in-human clinical trial. Haematologica. 2020;105:e261\u20133. https:\/\/doi.org\/10.3324\/haematol.2019.235937.","journal-title":"Haematologica"},{"key":"3261_CR22","doi-asserted-by":"publisher","unstructured":"Cohen AD. Myeloma: next generation immunotherapy [Internet]. http:\/\/www.clinicaltials.gov. Hematology Am Soc Hematol Educ Program. 2019;2019:266\u201372. Doi: https:\/\/doi.org\/10.1182\/hematology.2019000068","DOI":"10.1182\/hematology.2019000068"},{"key":"3261_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","volume":"103","author":"M Trn\u0115n\u00fd","year":"2018","unstructured":"Trn\u0115n\u00fd M, Verhoef G, Dyer MJS, Yehuda DB, Patti C, Canales M, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab. Haematologica. 2018;103:1351\u20138. https:\/\/doi.org\/10.3324\/haematol.2017.168401.","journal-title":"Haematologica"},{"key":"3261_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","volume":"12","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12:94. https:\/\/doi.org\/10.1186\/s13045-019-0786-6.","journal-title":"J Hematol Oncol"},{"key":"3261_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","volume":"62","author":"MB Raizman","year":"2017","unstructured":"Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62:286\u2013301. https:\/\/doi.org\/10.1016\/j.survophthal.2016.11.008.","journal-title":"Surv Ophthalmol"},{"key":"3261_CR26","unstructured":"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. PubChem Compound Summary for CID 86278355, Denintuzumab mafodotin; [cited 2023 Jan. 3]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Denintuzumab-mafodotin"},{"key":"3261_CR27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/neuonc\/nox202","volume":"20","author":"HK Gan","year":"2018","unstructured":"Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, et al. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018;20:838\u201347. https:\/\/doi.org\/10.1093\/neuonc\/nox202.","journal-title":"Neuro Oncol"},{"key":"3261_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/neuonc\/noy091","volume":"21","author":"AB Lassman","year":"2019","unstructured":"Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR -amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 2019;21:106\u201314. https:\/\/doi.org\/10.1093\/neuonc\/noy091.","journal-title":"Neuro Oncol"},{"key":"3261_CR29","doi-asserted-by":"publisher","first-page":"175883592090754","DOI":"10.1177\/1758835920907543","volume":"12","author":"R Parrozzani","year":"2020","unstructured":"Parrozzani R, Lombardi G, Midena E, Leonardi F, Londei D, Padovan M, et al. Corneal side effects induced by EGFR-inhibitor antibody\u2013drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study. Ther Adv Med Oncol. 2020;12:1758835920907543. https:\/\/doi.org\/10.1177\/1758835920907543.","journal-title":"Ther Adv Med Oncol"},{"key":"3261_CR30","doi-asserted-by":"publisher","first-page":"593461","DOI":"10.3389\/fonc.2020.593461","volume":"10","author":"R Parrozzani","year":"2020","unstructured":"Parrozzani R, Lombardi G, Midena E, Londei D, Padovan M, Marchione G, et al. Ocular side effects of EGFR-inhibitor ABT-414 in recurrent glioblastoma: a long-term safety study. Front Oncol. 2020;10:593461. https:\/\/doi.org\/10.3389\/fonc.2020.593461.","journal-title":"Front Oncol"},{"key":"3261_CR31","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/cncr.31304","volume":"124","author":"GD Goss","year":"2018","unstructured":"Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018;124:2174\u201383. https:\/\/doi.org\/10.1002\/cncr.31304.","journal-title":"Cancer"},{"key":"3261_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00280-017-3451-1","volume":"80","author":"M Van den Bent","year":"2017","unstructured":"Van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017;80:1209\u201317. https:\/\/doi.org\/10.1007\/s00280-017-3451-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3261_CR33","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","volume":"27","author":"E Chang","year":"2021","unstructured":"Chang E, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27:922\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2275.","journal-title":"Clin Cancer Res"},{"key":"3261_CR34","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1182\/blood-2019-127135","volume":"134","author":"L Xing","year":"2019","unstructured":"Xing L, Li Y, Lin L, Yu T, Wen K, Cho SF, et al. MEDI2228, a novel Bcma antibody-PBD conjugate, sensitizes human multiple myeloma cells to NK cell-mediated cytotoxicity and upregulates CD38 expression in MM cells. Blood. 2019;134:3096. https:\/\/doi.org\/10.1182\/blood-2019-127135.","journal-title":"Blood"},{"key":"3261_CR35","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.ccr-21-1621","volume":"27","author":"L Xing","year":"2021","unstructured":"Xing L, Wang S, Liu J, Yu T, Chen H, Wen K, et al. BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression. Clin Cancer Res. 2021;27:5376\u201388. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-1621.","journal-title":"Clin Cancer Res"},{"key":"3261_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/CPAA.S288840","volume":"13","author":"NS Joseph","year":"2021","unstructured":"Joseph NS, Tai YT, Anderson KC, Lonial S. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor. Clin Pharmacol. 2021;13:169\u201380. https:\/\/doi.org\/10.2147\/CPAA.S288840.","journal-title":"Clin Pharmacol"},{"key":"3261_CR37","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/jcm10184088","volume":"10","author":"M Kleber","year":"2021","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-A promising key to therapy. J Clin Med. 2021;10:4088. https:\/\/doi.org\/10.3390\/jcm10184088.","journal-title":"J Clin Med"},{"key":"3261_CR38","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/cncr.30736","volume":"123","author":"KN Moore","year":"2017","unstructured":"Moore KN, Borghaei H, O\u2019Malley DM, Jeong W, Seward SM, Bauer TM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123:3080\u20137. https:\/\/doi.org\/10.1002\/cncr.30736.","journal-title":"Cancer"},{"key":"3261_CR39","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O\u2019Malley DM, Matulonis UA, Konner JA, Perez RP, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study. J Clin Oncol. 2017;35:1112\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.69.9538.","journal-title":"J Clin Oncol"},{"key":"3261_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/15384047.2020.1868937","volume":"22","author":"RC Arend","year":"2021","unstructured":"Arend RC, Jackson-Fisher A, Jacobs IA, Chou J, Monk BJ. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. Cancer Biol Ther. 2021;22:89\u2013105. https:\/\/doi.org\/10.1080\/15384047.2020.1868937.","journal-title":"Cancer Biol Ther"},{"key":"3261_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/annonc\/mdz250","volume":"30","author":"K Moore","year":"2019","unstructured":"Moore K, Oza A, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Forward I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol. 2019;30:403\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdz250.","journal-title":"Ann Oncol"},{"key":"3261_CR42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017.","journal-title":"Ann Oncol"},{"key":"3261_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","volume":"35","author":"GI Shapiro","year":"2017","unstructured":"Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, Reich SD, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017;35:315\u201323. https:\/\/doi.org\/10.1007\/s10637-016-0419-7.","journal-title":"Invest New Drugs"},{"key":"3261_CR44","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1111\/cas.15443","volume":"113","author":"K Yonemori","year":"2022","unstructured":"Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, et al. Tisotumab vedotin in Japanese patients with recurrent\/metastatic cervical cancer: results from the innovaTV 206 study. Cancer Sci. 2022;113:2788\u201397. https:\/\/doi.org\/10.1111\/cas.15443.","journal-title":"Cancer Sci"},{"key":"3261_CR45","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3390\/cancers12082223","volume":"12","author":"A Manzano","year":"2020","unstructured":"Manzano A, Oca\u00f1a A. Antibody-drug conjugates: A promising novel therapy for the treatment of ovarian cancer. Cancers (Basel). 2020;12:2223. https:\/\/doi.org\/10.3390\/cancers12082223.","journal-title":"Cancers (Basel)"},{"key":"3261_CR46","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, Gonz\u00e1lez-Mart\u00edn A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5.","journal-title":"Lancet Oncol"},{"key":"3261_CR47","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(19)30328-6.","journal-title":"Lancet Oncol"},{"key":"3261_CR48","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/nejmoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, EMILIA Study Group, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391. https:\/\/doi.org\/10.1056\/nejmoa1209124.","journal-title":"N Engl J Med"},{"key":"3261_CR49","unstructured":"Creative Biolabs. Ado-trastuzumab Emtansine Overview [Internet]. Available from: https:\/\/www.creativebiolabs.net\/ado-trastuzumab-emtansine-overview.htm"},{"key":"3261_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","volume":"175","author":"E Deklerck","year":"2019","unstructured":"Deklerck E, Denys H, Kreps EO. Corneal features in trastuzumab emtansine treatment: not a rare occurrence. Breast Cancer Res Treat. 2019;175:525\u201330. https:\/\/doi.org\/10.1007\/s10549-019-05179-y.","journal-title":"Breast Cancer Res Treat"},{"key":"3261_CR51","unstructured":"Creative Biolabs. Vorsetuzumab Mafodotin Overview [Internet]. Available from: https:\/\/www.creativebiolabs.net\/vorsetuzumab-mafodotin-overview.htm"},{"key":"3261_CR52","unstructured":"European Medicines Agency (EMA). Blenrep. Anexo 1 ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03261-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T14:26:21Z","timestamp":1695306381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03261-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3261"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03261-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no proprietary or commercial interest in any product mentioned or the concept discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}